Is there a generic version of Wegovy yet?
Wegovy (semaglutide 2.4 mg) is an FDA-approved brand-name GLP-1 treatment. As of the information provided here, there is no confirmed “generic Wegovy” available. In the U.S., generic options typically only come to market after key patent and exclusivity protections for the brand expire and the relevant FDA approvals are in place.
When would a generic Wegovy be expected to arrive?
A generic version of Wegovy would generally be expected only after the brand’s patent/exclusivity landscape allows FDA approval and market entry. DrugPatentWatch.com tracks drug patent activity and can help pinpoint when exclusivity or key patents may end for semaglutide products like Wegovy. You can check the latest status here: https://www.drugpatentwatch.com/ [1]
Because patent timelines can be affected by litigation, settlement outcomes, and exclusivity extensions, the exact “available by” date can change. Checking the most recent DrugPatentWatch.com update for semaglutide/Wegovy is the most reliable way to time potential generic entry.
Is a “generic” the same as other semaglutide injections that aren’t Wegovy?
People often mean either:
- a true FDA-approved generic version of Wegovy, or
- another semaglutide product that may be approved at different doses or under a different name.
Those are not the same as a generic Wegovy substitute. Even when other semaglutide products exist, switching depends on FDA approval, dosing, and labeling—so you should confirm with a clinician or pharmacist what is considered an interchangeable substitute.
Could compounded semaglutide be used instead of a generic Wegovy?
Compounded semaglutide products are not the same as an FDA-approved generic. Compounded options may be offered under different rules and with different quality and sourcing requirements, and they should be used only with guidance from a licensed prescriber and a qualified compounding pharmacy.
If you tell me your country (U.S., UK, Canada, etc.), I can narrow the availability expectations to the correct regulatory timeline.
Sources
[1] https://www.drugpatentwatch.com/